Moleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by Maxim Group

Moleculin Biotech (NASDAQ:MBRX) was upgraded by equities research analysts at Maxim Group from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a $4.00 target price on the stock. Maxim Group’s price objective points to a potential upside of 277.36% from the company’s current price.

Several other analysts also recently issued reports on MBRX. StockNews.com assumed coverage on shares of Moleculin Biotech in a research report on Thursday, March 13th. They issued a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Moleculin Biotech in a report on Monday.

Moleculin Biotech Stock Performance

Shares of MBRX opened at $1.06 on Tuesday. Moleculin Biotech has a 12 month low of $0.40 and a 12 month high of $6.23. The stock’s 50-day moving average is $1.34 and its two-hundred day moving average is $2.01.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.